NEW YORK, May 15, 2013 /PRNewswire/ -- Venture capital (VC) funding in the Life Sciences sector, which includes the Biotechnology and Medical Device industries, dropped in volume and value during the first quarter of 2013 according to a new PwC US report, "Capital Crunch," that includes data from the PricewaterhouseCoopers LLP/National Venture Capital Association MoneyTree™ Report, based on data from Thomson Reuters.
Venture capitalists invested $1.4 billion in 167 Life Sciences deals during the first quarter of 2013. When compared with the same quarter of last year, that performance represented a drop of 14 percent in dollars and 16 percent in the number of deals. Quarter-over-quarter life sciences funding suffered a greater drop of 28 percent in dollars and 23 percent in deals. The first quarter of 2013 marks the lowest number of Life Sciences deals since the first quarter of 2009.
"As the number of venture capital funds continued to shrink, less capital-intensive industries — notably, software — attracted a greater share of the limited dollars available," said Tracy T. Lefteroff , global managing partner of the venture capital practice at PwC US. "The high level of funding needed, comparatively long time to market, and regulatory uncertainty can hinder the ability of life sciences companies to attract venture capital, especially during times of limited fundraising. Capital-efficient companies that have shorter time frames to a liquidity event — whether that is M&A or IPO — are often more successful in these times in attracting the attention of investors."
For all sectors, ventu
|SOURCE PwC US|
Copyright©2012 PR Newswire.
All rights reserved